Hiroaki Shimokawa

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology

Jelena R. Ghadri, Ilan S. Wittstein, Abhiram Prasad et al. · European Heart Journal · 2018 · 1.6K citations · Full text

Medicine, Cardiology, Internal Medicine +17

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén et al. · The Lancet · 2017 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Paul M. Ridker, Jean MacFadyen, Peter Libby et al. · The Lancet · 2017 · 886 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +8

International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management

Jelena R. Ghadri, Ilan S. Wittstein, Abhiram Prasad et al. · European Heart Journal · 2018 · 867 citations · Full text

Medicine, Cardiology, Neurology +9